PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
 
J Clin Invest. Mar 1, 2003; 111(5): 749–758.
PMCID: PMC151897

c-Fms and the αvβ3 integrin collaborate during osteoclast differentiation

Abstract

β3 integrin–null osteoclasts are dysfunctional, but their numbers are increased in vivo. In vitro, however, the number of β3–/– osteoclasts is reduced because of arrested differentiation. This paradox suggests cytokine regulation of β3–/– osteoclastogenesis differs in vitro and in vivo. In vitro, additional MCSF, but not receptor activator of NF-κB ligand (RANKL), completely rescues β3–/– osteoclastogenesis. Similarly, activation of extracellular signal-regulated kinases (ERKs) and expression of c-Fos, both essential for osteoclastogenesis, are attenuated in β3–/– preosteoclasts, but completely restored by additional MCSF. In fact, circulating and bone marrow cell membrane-bound MCSFs are enhanced in β3–/– mice, correlating with the increase in the osteoclast number. To identify components of the MCSF receptor that is critical for osteoclastogenesis in β3–/– cells, we retrovirally transduced authentic osteoclast precursors with chimeric c-Fms constructs containing various cytoplasmic domain mutations. Normalization of osteoclastogenesis and ERK activation, in β3–/– cells, uniquely requires c-Fms tyrosine 697. Finally, like high-dose MCSF, overexpression of c-Fos normalizes the number of β3–/– osteoclasts in vitro, but not their ability to resorb dentin. Thus, while c-Fms and αvβ3 collaborate in the osteoclastogenic process via shared activation of the ERK/c-Fos signaling pathway, the integrin is essential for matrix degradation.

Introduction

All forms of osteoporosis represent enhanced bone-resorptive activity of osteoclasts (OCs), relative to the bone forming capacity of osteoblasts. Thus, curing this family of diseases will depend upon understanding how these cells are regulated.

Two molecules, MCSF and receptor activator of NF-κB ligand (RANKL), are essential and sufficient to promote osteoclastogenesis. MCSF, which is obligatory for macrophage maturation, binds its receptor, c-Fms, which dimerizes and autophosphorylates several tyrosine residues, thereby providing signals required for survival and proliferation of early OC precursors (1). Hence, MCSF deficiency, because of a virtual absence of OCs, prompts an osteopetrotic phenotype (2, 3).

While the role of MCSF in macrophage proliferation is established, less is known about its direct effect on OC differentiation. To explore this issue, our laboratory developed a chimeric strategy to identify the structural components of c-Fms that mediate signaling in macrophages and OCs (4). Tyrosine (Y) 559 and Y807 in the c-Fms cytoplasmic domain are essential for OC proliferation and differentiation, while tyrosine Y697, Y706, and Y721, which are dispensable for macrophage proliferation, exert no impact on wild-type OCs (4).

Integrins are transmembrane proteins that comprise α and β subunits. These heterodimers mediate cell-cell and cell-matrix interactions and generate intracellular signals when occupied by ligands (5), or upon treatment of cells with growth factors or cytokines (6). The integrin αvβ3 is expressed by OCs, and binding of this complex to bone is pivotal to the resorptive process (7). Since pharmacological blockade of αvβ3 prevents experimental postmenopausal osteoporosis (8), the integrin is currently a therapeutic target (9, 10). Despite the critical role played by αvβ3 in skeletal resorption, little is known about its involvement in osteoclastogenesis. However, the fact that commitment of macrophages to the OC phenotype requires matrix recognition is consistent with the concept that integrins are involved in OC differentiation (11).

The likelihood that both MCSF and the αvβ3 integrin regulate osteoclastogenesis raises the possibility that they induce similar intracellular signals that eventuate in OC differentiation. In fact, cross-talk between integrin and growth factor receptor signaling pathways regulates cell proliferation, differentiation, and survival (12). Potentiation of growth factor receptor signaling by integrins contributes to cell cycle progression, as growth factor–stimulated mitogenic signaling is transient in the absence of integrin-mediated cell adhesion. For example, growth factors rapidly provoke the extracellular signal-regulated kinase (ERK) pathway, but prolongation of such activation requires cell adhesion (1214).

ERK activation is central to survival of hematopoietic cells (15) and mature OCs (16). Moreover, induction of this MAPK cascade is indispensable for proliferation and differentiation of selected cells in response to growth factors. In some circumstances, transient stimulation of the ERK cascade leads to cell proliferation, whereas sustained activation prompts differentiation (17). Because prolonged ERK activation results in nuclear translocation (1820), the enhanced cellular maturation attending this event may reflect modulated gene expression via transcription factor phosphorylation by the kinase. For example, prolonged ERK activation is required for stable expression of c-Fos (21), a transcription factor essential for osteoclastogenesis whose gene is transactivated, in macrophages, by MCSF (2224).

Because little is known about the impact of αvβ3 on osteoclastogenesis, we turned to this issue. We find that bone marrow macrophages (BMMs) derived from β3–/– mice, when plated in standard osteoclastogenic conditions, fail to normally differentiate into OCs. Interestingly, while increased RANKL levels are ineffective, enhanced MCSF completely rescues the differentiation defect in β3–/– OC precursors, an event mediated by c-Fms Y697. MCSF normalization of β3–/– osteoclastogenesis requires prolonged ERK signaling and enhanced c-Fos expression, but the integrin, per se, is needed for matrix degradation.

Methods

Construction and expression of retroviral vector expressing EpoR/c-Fms chimera and c-Fos.

We constructed erythropoietin receptor/c-Fms chimeras that consisted of the external domain of the erythropoietin receptor (EpoR) linked to the transmembrane and intracellular domains of c-Fms. Individual chimeras contained single tyrosine-to-phenylalanine point mutation in the cytoplasmic tail. We used the pMX-puro retroviral vector to express these chimeras, as described previously (4). pBabe-puro/c-Fos vector was kindly provided by Erwin Wagner (Research Institute of Molecular Pathology, Vienna, Austria)(25). The plasmids were transiently transfected into Phoenix-E cells using LipofectAmine Plus (Life Technologies Inc., Rockville, Maryland, USA).

Infection of BMMs.

We isolated BMMs from bone marrow of 4- to 8-week-old mice, cultured them overnight in α-MEM containing 10% heat-inactivated FBS, and subjected them to Ficoll-Hypaque gradient purification as described previously (26). We then collected 5 × 106 cells at the gradient interface and plated them in a p100 suspension culture dish (Corning Inc. Costar, New York, New York, USA) in the presence of 1:10 CMG14-12 culture supernatant (CMG) (27), which contained the equivalent of 240 μg/ml of recombinant MCSF. After 2 days, cells were transduced with virus for 24 hours in the presence of 1:10 CMG supernatant and 4 μg/ml polybrene (Sigma-Aldrich, St. Louis, Missouri, USA). Transduced cells were selected for an additional 3–5 days in puromycin-containing medium prior to analysis of osteoclastogenesis.

In vitro generation of OCs and bone resorption assay.

BMMs from β3+/+ and β3–/– mice were cultured in α-MEM containing 10% heat-inactivated FBS in the presence of 100 ng/ml RANKL and increasing concentrations of MCSF (from 10 to 100 ng/ml) in 96-well tissue-culture plates. β3–/– BMMs transduced with pBabe/c-Fos were cultured in the presence of 100 ng/ml RANKL and 10 ng/ml MCSF. Cells were fixed and stained for tartrate-resistant acid phosphatase (TRAP) activity after 3, 5, 7, or 10 days in culture, using a commercial kit (Sigma-Aldrich 387-A). BMMs transfected with the different erythropoietin/c-Fms mutants were cultured in the presence of 100 ng/ml RANKL and 25 U/ml recombinant human erythropoietin (Epo). Bone resorption was performed using β3+/+ or β3–/– pre-OCs retrovirally transduced with pBabe vector alone or with pBabe/c-Fos cultured for 4 additional days under the indicated osteoclastogenic condition. Cells were fixed and stained with TRAP or removed by brief treatment with 2N NaOH. The resorptive pits were visualized by hematoxylin staining.

Proliferation assay.

BMMs from β3+/+ and β3–/– mice were cultured in the presence of different concentrations of MCSF (from 6.25 to 100 ng/ml) with or without 100 ng/ml RANKL. After 3 days, the number of viable cells was measured using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; Sigma-Aldrich) method. Briefly, 10 μl MTT (5 mg/ml) was added to 100 μl culture medium in each well and incubated at 37°C for 4 hours. One hundred fifty microliters 0.04N HCl in isopropanol was added to each well to stop the reaction, and MTT absorbance was determined at an OD of 570 nm. Six wells were used for each treatment, and experiments were repeated twice.

Apoptosis assay.

β3+/+ or β3–/– BMMs were cultured with 10 ng/ml or 100 ng/ml MCSF alone or in combination with 100 ng/ml RANKL, the latter added at initiation of culture (day 4) or after 2 days (day 2). As positive control for cell death, the cytokines were removed from half the wells during the last 24 hours of the culture period. The magnitude of apoptosis was determined by ELISA (Cell Death Detection ELISA; Roche Molecular Biochemicals, Mannheim, Germany). Briefly, culture medium was carefully removed and the provided lysis buffer was added to each well for 30 minutes at room temperature. Twenty microliters of the supernatant was immediately analyzed according to the manufacturer’s directions. Data represent mean ± SE from three independent experiments.

ELISA and Western blot for MCSF.

Circulating levels of MCSF were detected in the serum of three different β3+/+ and β3–/– mice (mouse MCSF Quantikine ELISA; R&D Systems Inc., Minneapolis, Minnesota, USA) according to the manufacturer’s directions. Membrane-bound MCSF was detected in bone marrow cells, flushed from tibia and femur with a minimal amount of PBS, and immediately lysed in 10 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.2% sodium deoxycholate, 1% NP 40, 1 mM NaF, 2 mM Na3VO4, and protease inhibitor cocktail (Sigma-Aldrich). Fifty micrograms of proteins were loaded under nonreducing conditions in a 12% SDS gel, transferred to nitrocellulose membranes using a semidry blotter (Bio-Rad Laboratories Inc., Richmond, California, USA), and incubated in blocking solution (5% nonfat dry milk in TBS containing 0.1% Tween-20) for 1 hour, to reduce nonspecific binding. Western analysis was performed using the anti-MCSF mAb 5A1, kindly provided by H.-S. Lin (Washington University) (28), and showed a 22-kDa band corresponding to membrane-bound MCSF. Equal loading was confirmed by β-actin (Sigma-Aldrich) blot.

Western analysis.

BMMs from β3+/+ and β3–/– mice were cultured for 3 days in the presence of 100 ng/ml RANKL and 10 ng/ml purified MCSF, starved for 2 hours, and stimulated for the indicated times with 10 or 100 ng/ml purified MCSF. BMMs transfected with EpoR/c-Fms chimeras were grown in the presence of RANKL and MCSF, starved of serum and growth factors, and stimulated with 25 U/ml Epo before lysis. A different set of experiments was performed using day 3 β3+/+ and β3–/– pre-OCs. Cells were lifted with trypsin/EDTA solution, resuspended in a serum-free medium, and plated onto dishes coated with 5 μg/ml osteopontin (OPN) for the indicated times. Cells were then washed twice with ice-cold PBS and lysed in the buffer containing 10 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.2% sodium deoxycholate, 1% NP 40, 1 mM NaF, 2 mM Na3VO4, and 1× protease inhibitor cocktail (Sigma-Aldrich). Forty micrograms per milliliter of cell lysates were boiled in the presence of SDS sample buffer for 5 minutes and subjected to electrophoresis on 8% SDS-PAGE. For ERK-MAPK Western analysis, a polyclonal anti–ERK1/2 or an anti–phospho-p42/p44 MAPK polyclonal antibody was used (Cell Signaling Technology Inc., Beverly, Massachusetts, USA). For RSK analysis, the anti–phospho-p90RSK antibody was purchased from Cell Signaling Technology Inc., and the monoclonal anti-RSK antibody was from BD Transduction Laboratories Inc. (San Diego, California, USA). Anti–c-Fos and anti–c-Fms were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, California, USA).

RNA preparation and RT-PCR analyses.

Total RNA from cultured cells was isolated by the guanidine/phenol method. For RT-PCR analysis, cDNAs were synthesized from 1 μg of total RNA using reverse transcriptase and oligo-dT primers in a volume of 20 μl, and the reaction mixture was finally adjusted to 100 μl with TE buffer for PCR analysis. PCR was performed with 1 μl of cDNA reaction mixture using Platinum Pfx polymerase (Invitrogen Corp., Carlsbad, California, USA) and appropriate primers in a volume of 50 μl. The following primers were used: for cathepsin K, 5′-GGAAGAAGACTCACCAGAAGC-3′ and 3′-GCTATATAGCCGCCTCCACAG-5′; for MMP-9, 5′-CCTGTGTGTTCCCGTTCATCT-3′ and 3′-CGCTGGAATGATCTAAGCCCA; for TRAP, 5′-ACAGCCCCCCACTCCCACCCT-3′ and 3′-TCAGGGTCTGGGTCTCCTTGG-5′; for microphthalmia transcription factor (MITF), 5′-ACCATCAGCAACTCCTGTCC-3′ and 3′-GAATCGGATCATCAAGCAAGAA-5′; for calcitonin receptor, 5′-CATTCCTGTTACTTGGTTGGC-3′ and 3′-AGCAATCGACAAGGAGTGAC; and for GAPDH, 5′-ACTTTGTCAAGCTCATTTCC-3′ and 3′-TGCAGCGAACTTTATTGATG-5′. The samples were transferred to a programmable thermal cycler (Hybaid US, Franklin, Massachusetts, USA) that had been preheated to 95°C, and incubated for 21–40 PCR cycles. Each cycle consisted of a denaturation step at 95°C for 1 minute, an annealing step at 60°C for 1 minute, and an extension step at 72°C for 1 minute. Ten-microliter aliquots of PCR products were separated by electrophoresis on a 1.5% agarose gel.

Statistics.

All data are presented as mean ± SEM.

Results

Osteoclastogenesis by β3–/– BMMs is rescued by high-dose MCSF.

To assess the role of αvβ3 in osteoclastogenesis, we measured the capacity of β3–/– BMMs to differentiate into mature OCs when cultured in standard osteoclastogenic conditions. β3+/+ and β3–/– BMMs were maintained in 10 ng/ml MCSF and 100 ng/ml RANKL for 3, 5, 7, or 10 days, and differentiated OCs were detected as a function of multinucleation and TRAP expression. TRAP-expressing β3+/+ mononuclear and binuclear pre-OCs and a few small multinuclear OCs appeared by day 3 and became fully differentiated by day 7–10 (Figure (Figure1a).1a). In contrast, the capacity of β3–/– BMMs to differentiate into pre-OCs by day 3 or assume the fully OC phenotype by day 10 was arrested (Figure (Figure1a).1a). Increasing RANKL levels to 500 ng/ml did not impact the osteoclastogenic defect (not shown). On the other hand, OC formation by β3–/– BMMs normalized when MCSF concentration was increased from 10 to 100 ng/ml without RANKL concentration being altered (Figure (Figure1b).1b). While characteristic β3+/+ OCs appeared earlier (i.e., by day 3) under the latter conditions, the impact of increased MCSF on β3–/– BMMs was striking. High-dose MCSF promoted differentiation of these mutant macrophages into TRAP-expressing pre-OCs, and into OCs indistinguishable from WT, by day 7–10.

Figure 1
High-dose MCSF rescues β3–/– osteoclastogenesis. BMMs derived from β3+/+ or β3–/– mice were cultured in RANKL and either 10 ng/ml (a) or 100 ng/ml (b) MCSF for 3, 7, or 10 days, fixed ...

We next asked whether the increase in β3–/– OC number induced by high-dose MCSF reflects enhanced proliferation and/or attenuated apoptosis. Proliferation of β3–/– BMMs in increasing concentrations of MCSF, with (Figure (Figure2b)2b) or without (Figure (Figure2a)2a) RANKL, mirrored that of WT cells. Interestingly, along with their failure to differentiate into OCs, the rate of constitutive and stimulated (by 24-hour cytokine withdrawal) apoptosis of β3–/– BMMs was reduced in low-dose MCSF plus RANKL (Figure (Figure2c).2c). Programmed death of these mutant cells was, however, indistinguishable from that of their WT counterparts when ambient MCSF was enhanced (Figure (Figure2d).2d). Thus, the increase in the number of β3–/– OCs that was induced by high-dose MCSF reflects stimulated differentiation and neither accelerated division nor arrested apoptosis of OC precursors.

Figure 2
The capacity of high-dose MCSF to increase β3–/– OC number is not due to accelerated proliferation or arrested apoptosis. β3+/+ or β3–/– BMMs were cultured with increasing concentrations ...

To determine whether the profound morphological changes in cultured β3–/– BMMs that were prompted by high-dose MCSF represented bona fide OC differentiation, we assessed expression of various markers of mature OCs. β3+/+ and β3–/– cells were cultured for 3 days in RANKL and low-dose (10 ng/ml) or high-dose (100 ng/ml) MCSF. RNA was extracted, and TRAP, MMP-9, and calcitonin receptor mRNA levels were determined by RT-PCR (Figure (Figure3).3). We also assessed mRNA expression of cathepsin K (CK), a lysosomal cysteine protease involved in dissolution of bone organic matrix (29), and microphthalmia transcription factor (MITF), known to regulate transcription of TRAP and CK (30). Confirming arrest of OC differentiation, β3–/– BMMs cultured in RANKL plus low-dose MCSF contained twofold less TRAP, threefold less MMP-9, and threefold less CK mRNA than did β3+/+ cells. MITF and calcitonin receptor were particularly dampened in β3–/– cells (fivefold). Consistent with its morphological effects, high-dose MCSF enhanced levels of each of the indicated OC differentiation markers in β3-null cells to approximately those found in their WT counterparts exposed to the standard concentration of the cytokine. Reflecting induction of WT osteoclastogenesis, high-dose cytokine also stimulated OC marker expression by β3+/+ pre-OCs. As expected, none of the indicated species of mRNA was substantially expressed by β3+/+ or β3–/– BMMs cultured only with MCSF. Thus, failed osteoclastogenesis of β3–/– cells cultured in low-dose MCSF reflects arrested differentiation that is corrected by increased concentrations of the cytokine.

Figure 3
High-dose MCSF promotes expression of osteoclastogenic markers in β3–/– pre-OCs. BMMs derived from β3+/+ or β3–/– mice were cultured with RANKL and either low-dose (10 ng/ml; LD) ...

MCSF is increased in β3–/– mice in vivo.

The data presented thus far are consistent with the hypothesis that the increased OC number extant in αvβ3 deficient mice reflects the impact of abundant MCSF. In fact, circulating levels of the cytokine were increased about 30% in the mutant animals (Figure (Figure4a).4a). In order to measure the MCSF level in the bone microenvironment, freshly isolated bone marrow cells were lysed and subjected to Western blot analysis. A 22-kDa band, corresponding to the membrane-residing form of MCSF (31), was detected in the lysates derived from both genotypes (Figure (Figure4b).4b). Importantly, membrane MCSF expression was enhanced threefold in β3–/– mice (Figure (Figure44c).

Figure 4
MCSF is increased in β3–/– mice in vivo. Circulating and bone-microenvironment MCSF levels from three β3–/– and three β3+/+ mice were measured by ELISA (a) or Western blot (b and ...

Defective ERK signaling in β3–/– pre-OCs is rescued by high-dose MCSF.

The fact that high-dose MCSF compensates for lack of αvβ3 suggests that a common signaling pathway emanates from the cytokine receptor and the integrin. Because c-Fms or β3 integrin engagement activates ERKs (32, 33), these MAPKs are possible downstream candidates. Furthermore, ERK phosphorylation correlates with proliferation, survival, and differentiation of various cells (20, 34). Hence, we determined the ability of β3+/+ or β3–/– cells to induce ERK phosphorylation upon adhesion to the αvβ3 substrate OPN.

Day 3 pre-OCs, generated from β3+/+ or β3–/– BMMs, were lifted and replated on OPN in the absence of serum. After 15, 30, 60, or 120 minutes, adherent cells were lysed and ERK activation, as manifest by its phosphorylation, was assessed by immunoblot. Fifteen minutes of attachment of β3+/+ pre-OCs to the αvβ3 ligand prompted ERK1/2 phosphorylation, the magnitude of which remained unaltered for at least 120 minutes (Figure (Figure5).5). In contrast, activation of MAPK in β3–/– cells attached to OPN was greatly reduced and short-lived. Therefore, αvβ3 is required for OPN-induced ERK activation in pre-OCs.

Figure 5
Adhesion-induced ERK activation is defective in β3–/– pre-OCs. β3+/+ or β3–/– BMMs were maintained for 3 days in low-dose MCSF and 100 ng/ml RANKL. The cells were detached and replated ...

We next asked whether, like osteoclastogenesis, ERK activation in response to MCSF requires a high dose of the cytokine to compensate for lack of the integrin. Thus, pre-OCs derived from BMMs exposed to RANKL and low-dose MCSF for 3 days were stimulated with low- or high-dose MCSF for 2, 5, or 15 minutes. As seen in Figure Figure6,6, the magnitude and duration of ERK phosphorylation was dampened in β3–/– cells exposed to low-dose MCSF. In response to high-dose MCSF, however, ERK phosphorylation in WT and β3-null pre-OCs was indistinguishable. Thus, αvβ3 and c-Fms share a common intracellular signaling pathway, a component of which involves ERK activation.

Figure 6
High-dose MCSF rescues ERK activation in β3–/– pre-OCs. Pre-OCs derived from BMMs treated with RANKL and low-dose MCSF for 3 days were starved for 2 hours in serum-free medium and exposed to 10 or 100 ng/ml MCSF, with time. ERK ...

c-FmsY697 is specifically required for osteoclastogenesis in the absence of αvβ3.

The cytoplasmic domain of c-Fms contains seven tyrosine residues, which are potentially phosphorylated upon receptor occupancy (3537). To determine which, if any, such residues mediate the differentiating influence of high-dose MCSF on β3–/– pre-OCs, we retrovirally expressed a chimeric protein comprising the external domain of the EpoR linked to the transmembrane and cytoplasmic domains of c-Fms. BMMs expressing the EpoR/c-Fms chimera differentiate into bone-resorbing OCs when treated with RANKL and MCSF, which binds endogenous c-Fms receptor. Importantly, these same transductants, exposed to RANKL and Epo, which recognizes the chimeric receptor, also undergo osteoclastogenesis (4).

The same number of puromycin-selected β3+/+ and β3–/– BMMs, transfected with either WT EpoR/c-Fms receptor or an EpoR/c-Fms construct carrying a Y697F to phenyalanine (F) (Y697F), Y721F, or Y921F mutation, were cultured for 7 days in the presence of RANKL and Epo. Expression of all forms of the chimeric receptor was equivalent (Figure (Figure7a).7a). Since BMMs carrying EpoR/c-FmsY559F or EpoR/c-FmsY807F are incapable of OC differentiation (4), these mutants were not studied.

Figure 7
c-FmsY697 is specifically required for osteoclastogenesis in the absence of αvβ3. (a) Equal numbers of β3+/+ and β3–/– BMMs were retrovirally transduced with vector alone, nonmutated EpoR/c-Fms ...

Exposure to Epo and RANKL of either β3+/+ or β3–/– BMMs expressing WT EpoR/c-Fms resulted in generation of numerous OCs (Figure (Figure7b).7b). This observation indicates that the nonmutated chimeric receptor, like endogenous c-Fms, rescues the defect in β3–/– OC differentiation. In contrast, while ligand-occupied EpoR/c-FmsY697F failed to impact osteoclastogenesis in β3+/+ cells, the same mutant resulted in 3.5-fold fewer β3–/– OCs. The chimeric receptor bearing the mutation Y721F (Figure (Figure7b),7b), Y706F (not shown), or Y921F (not shown) exerted no effect on Epo-induced osteoclastogenesis. Thus, while it is not necessary in BMMs expressing αvβ3, c-FmsY697F mediates osteoclastogenesis in cells lacking the integrin.

c-FmsY697 is required for sustained ERK phosphorylation in pre-OCs lacking αvβ3.

Having established a correlation between arrested OC differentiation and defective ERK phosphorylation, we asked whether the anti-osteoclastogenic effect of c-FmsY697F, in the absence of αvβ3, is mirrored by failure to activate this signaling pathway. β3–/– or β3+/+ pre-OCs, retrovirally transduced with different EpoR/c-Fms mutants, were cultured for 3 days in the presence of MCSF and RANKL, serum-starved, and stimulated with Epo for 0, 5, or 15 minutes (Figure (Figure8a).8a). Total ERK immunoblot established equal loading (Figure (Figure8b).8b). EpoR/c-Fms bearing Y721F or Y921F mutations phosphorylated ERKs in β3+/+ and β3–/– cells in a manner indistinguishable from that of the WT chimeric receptor. However, while it did not impact β3+/+ cells, EpoR/c-FmsY697F failed to sustain ERK activation in β3–/– OCs, in all other transductants, which persisted for at least 15 minutes after Epo exposure. Thus, in the absence of αvβ3, ERK phosphorylation is maintained via c-Fms occupancy, a process requiring Y697 in the cytoplasmic domain of this receptor tyrosine kinase.

Figure 8
c-FmsY697 is specifically required for sustained ERK phosphorylation in β3–/– pre-OCs. (a) BMMs from β3+/+ and β3–/– mice, transfected with the control EpoR/c-Fms (WT) or with the ...

High-dose MCSF rescues β3–/– osteoclastogenesis, but not resorptive function, via c-Fos expression.

Turning to candidate downstream molecules, we found that activation of the ERK1/2 substrate RSK2 was impaired in β3–/– pre-OCs stimulated with low-dose MCSF (Figure (Figure9a),9a), but not in those stimulated with high-dose MCSF (Figure (Figure9b).9b). Mirroring the results for ERKs, high-dose MCSF rescued RSK activation in β3–/– pre-OCs.

Figure 9
High-dose MCSF is required to activate RSK and c-Fos in β3–/– pre-OCs. β3+/+ and β3–/– BMMs exposed to RANKL and low-dose MCSF for 3 days were placed in serum-free medium for 2 hours ...

ERK induced c-Fos expression and its phosphorylation. In fact, c-Fos expression was enhanced in β3+/+ pre-OCs treated for 30 or 60 minutes with low-dose (Figure (Figure9c)9c) or high-dose (Figure (Figure9d)9d) MCSF. In contrast, and mirroring morphological rescue by the cytokine, c-Fos was induced in β3–/– cells only when they were treated with high-dose MCSF. Sixty minutes of exposure to high-dose cytokine, in all circumstances, promoted appearance of c-Fos. These data suggest that high-dose MCSF compensates for the lack of β3 by inducing c-Fos expression.

The fact that c-Fos is a target of ERK and is essential for osteoclastogenesis raised the possibility that its blunted expression, in β3–/– cells, is responsible for arrested OC differentiation. To test this hypothesis, β3–/– BMMs were retrovirally transduced with pBabe/c-Fos or vector alone, selected with puromycin for 5 days, and plated in the presence of RANKL and low-dose MCSF. While vector-transduced β3–/– cells remained unaltered, those overexpressing c-Fos became fully differentiated OCs, morphologically indistinguishable from their β3+/+ counterparts (Figure (Figure10a).10a). Immunoblot established that c-Fos expression by WT and overexpressing cells was equivalent (Figure (Figure1010b).

Figure 10
c-Fos overexpression by β3–/– cells rescues osteoclastogenesis but not matrix resorption. β3+/+ BMMs and β3–/– BMMs retrovirally transduced with pBabe vector (MOCK) or pBabe/c-Fos ...

To determine whether high-dose MCSF or c-Fos overexpression also rescues OC function, we plated equal numbers of committed pre-OCs on dentin. Four days later, we analyzed OC morphology and resorptive-pit formation. β3+/+ OCs, on dentin, assumed the typical “round” appearance of resorptive cells and excavated numerous, well-demarcated large pits (Figure (Figure10c).10c). In contrast, β3–/– cells in low-dose MCSF, while expressing TRAP, were largely mononuclear, generating only a few small resorptive lacunae. Interestingly, those mutant cells exposed to high-dose MCSF, or overexpressing c-Fos, formed large, spread polykaryons on dentin, a characteristic of nonresorbing OCs. These cells demonstrated a limited capacity to generate lacunae, providing further evidence that they were nonresorbing OCs. Thus, high-dose MCSF rescues the ability of β3–/– BMMs to differentiate into OCs, but αvβ3 is essential for these cells to express their full resorptive capacity.

Discussion

Mice lacking αvβ3 contain increased numbers of histologically normal, albeit dysfunctional, OCs and thus develop osteosclerosis (7, 26). Curiously, OC differentiation of β3–/– BMMs in vitro is blunted, and the OCs generated appear distinctly abnormal. This paradox suggests that the osteoclastogenic milieu in which β3–/– BMMs find themselves in vivo and in vitro differs. Importantly, the β3–/– mouse is markedly hypocalcemic (7), and thus almost certainly hyperparathyroid. This observation raises the possibility that the relative normalization of OC differentiation in vivo reflects the influence of excess parathyroid hormone, which mediates its osteoclastogenic effect by prompting expression of RANKL and MCSF (3841). Our data suggest that increased levels of the latter cytokine, in the bone microenvironment, may account for the observed in vitro versus in vivo differences. The fact that β3–/– mice are exposed to increased soluble MCSF and, particularly, enhanced membrane-residing MCSF in bone marrow cells provides compelling support of this posture.

Several groups have shown a correlation between increased OC number and elevated levels of MCSF. Kimble et al. highlighted a role for MCSF in estrogen deficiency–induced bone loss (42), and Lea et al. provided intriguing evidence that membrane MCSF is selectively upregulated following sex hormone withdrawal (31). Thus, our data are consistent with the conclusion of Yao et al. that membrane MCSF plays an important role in osteoblast-mediated osteoclastogenesis within the bone microenvironment (43).

The salutary impact of MCSF on β3–/– OC number reflects stimulated differentiation and not accelerated proliferation or arrested apoptosis. In fact, the magnitude of programmed cell death, while diminished in low-dose MCSF and RANKL, is normalized when MCSF is increased. These data are consistent with the fact that OCs are terminally differentiated, nonreplicating cells and hence are more likely to be susceptible to apoptosis than BMMs are. Thus, failure of low-dose MCSF to stimulate osteoclastogenesis of β3–/– BMMs likely prolongs the lifespan of these mononuclear precursors.

The ERK family of MAPKs is induced by many agonists, but the biological consequences of such induction in a given cell (i.e., proliferation or differentiation) are determined by quantitative differences in amplitude and duration of activation (44). Having shown that β3–/– osteoclastogenesis is dampened along with ERK activation, we asked whether high-dose MCSF, which rescues OC formation by αvβ3 deficient cells, also restores ERK signaling. In fact, when β3–/– pre-OCs are stimulated with high-dose MCSF, ERK is phosphorylated independent of the integrin. These data suggest that physiological osteoclastogenesis reflects cooperative ERK activation by both αvβ3 and MCSF. On the other hand, loss of the integrin obviates one means of ERK stimulation, which is compensated by high-dose MCSF.

The capacity of high-dose MCSF to rescue β3–/– OCs called our attention to the components of the cytokine’s receptor that regulate this event. To identify the c-Fms tyrosine residues that mediate β3–/– OC rescue and ERK activation in the context of primary precursor cells, we turned to a chimeric receptor consisting of an external component of EpoR and the transmembrane and cytoplasmic domains of the c-FMS. BMMs transduced with this chimera differentiate into OCs when stimulated with Epo, acting on the chimeric receptor, or with MCSF, through endogenous c-Fms.

We find that Y697 in the c-Fms cytoplasmic domain is essential for rescue of osteoclastogenesis by BMMs lacking αvβ3. Specifically, β3–/– BMMs transduced with EpoR/c-FmsY697F fail to differentiate into multinucleated OCs or to normally activate ERK. This observation is in keeping with the fact that, upon stimulation with MCSF, c-FmsY697 binds Grb-2 (37), which is an ERK-inducing molecule. Interestingly, the same EpoR/c-Fms mutant, namely Y697F, expressed in αvβ3-bearing cells is as effective as its WT counterpart in promoting osteoclastogenesis. Thus, a specific residue in the c-Fms cytoplasmic domain participates in the osteoclastogenic process only in the absence of an integrin also capable of activating ERK.

Our model proposes that αvβ3 and c-Fms share a common signaling pathway during OC differentiation. Specifically, expression of early osteoclastogenic markers is dependent on the integrin when pre-OCs are maintained in a low concentration of MCSF. Increasing levels of the cytokine override the differentiation defect in β3–/– cells, permitting normal OC formation. Thus, in the presence of limited concentrations of MCSF, signals derived from the αvβ3 integrin are likely to be indispensable for transcriptional activation of immediate-early-response genes. While MCSF is known to regulate cell proliferation and survival, these data establish that, in the context of the OC precursors that lack αvβ3, the cytokine also promotes differentiation.

c-Fos is crucial to osteoclastogenesis (22, 23). Since expression of the transcription factor, in other circumstances, is stimulated by activated ERK (21), this MAPK is a potential upstream inducer of c-Fos in OCs. In fact, decreased ERK phosphorylation in β3–/– pre-OCs, attended by deficient RSK activation, arrests c-Fos expression in response to low-dose MCSF. High-dose MCSF increases the intensity and duration of the ERK signal in these mutant cells, sustains activation of RSK, and, importantly, upregulates c-Fos.

Murphy et al. recently reported that prolonged ERK and RSK activation eventuates in enhanced c-Fos expression via phosphorylation-mediated stabilization of the protein (21). Their studies were performed, however, in transformed cells and are thus of unknown physiological relevance. Taken with the persistent ERK and RSK activation that appears in β3–/– pre-OCs exposed to high-dose MCSF, the increase in c-Fos, which is likely to be phosphorylated, may provide physiological validation of Murphy’s observations.

Our results indicate that MCSF promotes OC differentiation by upregulating c-Fos. Confirmation of this posture comes from the fact that β3–/– OCs overexpressing c-Fos are morphologically indistinguishable from those exposed to high-dose MCSF. Thus, αvβ3 and c-Fms mediate OC differentiation via the ERK/c-Fos pathway. Mirroring the in vivo situation, however, β3–/– OCs in which this pathway is activated, while well spread and multinucleated, fail to adequately resorb bone. This observation is in keeping with the fact that β3–/– OCs in vivo, when examined by electron microscopy, have abnormal ruffled membranes (7). Thus, while c-Fos expression is sufficient to promote OC formation in the absence of αvβ3, the integrin is pivotal to the matrix-degradative capacity of the cell.

Acknowledgments

This work was supported by NIH grants AR-48812 and AR-46852 (to F.P. Ross) and AR-48853, AR-46523, AR32788, and DK-56341 (Clinical Nutrition Research Unit) (to S.L. Teitelbaum); a grant from Pharmacia Corp. (to S.L. Teitelbaum); and grants from the Italian Foundation for Cancer Research and the Italian Space Agency (to A. Zallone).

Footnotes

Conflict of interest: The authors have declared that no conflict of interest exists.

Nonstandard abbreviations used: osteoclast (OC); receptor activator of NF-κB ligand (RANKL); extracellular signal-regulated kinase (ERK); erythropoietin (Epo); erythropoietin receptor (EpoR); tartrate-resistant acid phosphatase (TRAP); osteopontin (OPN); microphthalmia transcription factor (MITF).

References

1. Hamilton JA. CSF-1 signal transduction. J. Leukoc. Biol. 1997;62:145–155. [PubMed]
2. Felix R, et al. Impairment of macrophage colony-stimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op mouse. J. Bone Miner. Res. 1990;5:781–789. [PubMed]
3. Wiktor-Jedrzejczak W, et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc. Natl. Acad. Sci. U. S. A. 1990;87:4828–4832. [PubMed]
4. Feng X, et al. Tyrosines 559 and 807 in the cytoplasmic tail of the m-csf receptor play distinct roles in osteoclast differentiation and function. Endocrinology. 2002;143:4868–4874. [PubMed]
5. van der Flier A, Sonnenberg A. Function and interactions of integrins. Cell Tissue Res. 2001;305:285–298. [PubMed]
6. Eliceiri BP. Integrin and growth factor receptor crosstalk. Circ. Res. 2001;89:1104–1110. [PubMed]
7. McHugh KP, et al. Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest. 2000;105:433–440. [PMC free article] [PubMed]
8. Engleman VW, et al. A peptidomimetic antagonist of the αvβ3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J. Clin. Invest. 1997;99:2284–2292. [PMC free article] [PubMed]
9. Horton MA. Integrin antagonists as inhibitors of bone resorption: implications for treatment. Proc. Nutr. Soc. 2001;60:275–281. [PubMed]
10. Mousa SA. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Curr. Opin. Chem. Biol. 2002;6:534–541. [PubMed]
11. Miyamoto T, et al. An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B. Blood. 2000;96:4335–4343. [PubMed]
12. Renshaw MW, Ren XD, Schwartz MA. Growth factor activation of MAP kinase requires cell adhesion. EMBO J. 1997;16:5592–5599. [PubMed]
13. Lin TH, Chen Q, Howe A, Juliano RL. Cell anchorage permits efficient signal transduction between ras and its downstream kinases. J. Biol. Chem. 1997;272:8849–8852. [PubMed]
14. Roovers K, Davey G, Zhu X, Bottazzi ME, Assoian RK. Alpha5beta1 integrin controls cyclin D1 expression by sustaining mitogen-activated protein kinase activity in growth factor-treated cells. Mol. Biol. Cell. 1999;10:3197–3204. [PMC free article] [PubMed]
15. Kinoshita T, et al. Raf/MAPK and rapamycin-sensitive pathways mediate the anti-apoptotic function of p21Ras in IL-3-dependent hematopoietic cells. Oncogene. 1997;15:619–627. [PubMed]
16. Miyazaki T, et al. Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J. Cell Biol. 2000;148:333–342. [PMC free article] [PubMed]
17. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995;80:179–185. [PubMed]
18. Chen RH, Sarnecki C, Blenis J. Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Mol. Cell. Biol. 1992;12:915–927. [PMC free article] [PubMed]
19. Nguyen TT, et al. Co-regulation of the mitogen-activated protein kinase, extracellular signal-regulated kinase 1, and the 90-kDa ribosomal S6 kinase in PC12 cells. Distinct effects of the neurotrophic factor, nerve growth factor, and the mitgenic factor, epidermal growth factor. J. Biol. Chem. 1993;268:9803–9810. [PubMed]
20. Traverse S, et al. EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor. Curr. Biol. 1994;4:694–701. [PubMed]
21. Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell Biol. 2002;4:556–564. [PubMed]
22. Grigoriadis AE, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science. 1994;266:443–448. [PubMed]
23. Johnson RS, Spiegelman BM, Papaloannou V. Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell. 1992;71:577–586. [PubMed]
24. Muller R, Curran T, Muller D, Guilbert L. Induction of c-fos during myelomonocytic differentiation and macrophage proliferation. Nature. 1985;314:546–548. [PubMed]
25. Matsuo K, et al. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat. Genet. 2000;24:184–187. [PubMed]
26. Feng X, et al. A Glanzmann’s mutation of the β3 integrin gene specifically impairs osteoclast function. J. Clin. Invest. 2001;107:1137–1144. [PMC free article] [PubMed]
27. Takeshita S, Kaji K, Kudo A. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J. Bone Miner. Res. 2000;15:1477–1488. [PubMed]
28. Lokeshwar BL, Lin HS. Development and characterization of monoclonal antibodies to murine macrophage colony-stimulating factor. J. Immunol. 1988;141:483–488. [PubMed]
29. Saftig P, et al. Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice. Adv. Exp. Med. Biol. 2000;477:293–303. [PubMed]
30. Weilbaecher KN, et al. Linkage of M-CSF signaling to Mitf, TFE3, and the osteoclast defect in Mitf(mi/mi) mice. Mol. Cell. 2001;8:749–758. [PubMed]
31. Lea CK, Sarma U, Flanagan AM. Macrophage colony stimulating-factor transcripts are differentially regulated in rat bone-marrow by gender hormones. Endocrinology. 1999;140:273–279. [PubMed]
32. Dey A, et al. Colony-stimulating factor-1 receptor utilizes multiple signaling pathways to induce cyclin D2 expression. Mol. Biol. Cell. 2000;11:3825–3848. [PMC free article] [PubMed]
33. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J. Cell Biol. 1998;140:1255–1263. [PMC free article] [PubMed]
34. Balmanno K, Cook SJ. Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene. 1999;18:3085–3097. [PubMed]
35. Reedijk M, et al. Tyr721 regulates specific binding of the CSF-1 receptor kinase insert to PI 3′-kinase SH2 domains: a model for SH2-mediated receptor-target interactions. EMBO J. 1992;11:1365–1372. [PubMed]
36. Tapley P, Kazlauskas A, Cooper JA, Rohrschneider LR. Macrophage colony-stimulating factor-induced tyrosine phosphorylation of c-fms proteins expressed in FDC-P1 and BALB/c 3T3 cells. Mol. Cell. Biol. 1990;10:2528–2538. [PMC free article] [PubMed]
37. van der Geer P, Hunter T. Mutation of Tyr697, a GRB2-binding site, and Tyr721, a PI 3-kinase binding site, abrogates signal transduction by the murine CSF-1 receptor expressed in Rat-2 fibroblasts. EMBO J. 1993;12:5161–5172. [PubMed]
38. Suda T, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 1999;20:345–357. [PubMed]
39. Yao GQ, et al. The cell-surface form of colony-stimulating factor-1 is regulated by osteotropic agents and supports formation of multinucleated osteoclast-like cells. J. Biol. Chem. 1998;273:4119–4128. [PubMed]
40. Weir EC, et al. Macrophage colony-stimulating factor release and receptor expression in bone cells. J. Bone Miner. Res. 1993;8:1507–1518. [PubMed]
41. Weir EC, Lowik CW, Paliwal I, Insogna KL. Colony stimulating factor-1 plays a role in osteoclast formation and function in bone resorption induced by parathyroid hormone and parathyroid hormone-related protein. J. Bone Miner. Res. 1996;11:1474–1481. [PubMed]
42. Kimble RB, Srivastava S, Ross FP, Matayoshi A, Pacifici R. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production. J. Biol. Chem. 1996;271:28890–28897. [PubMed]
43. Yao G-Q, Sun BH, Weir EC, Insogna KL. A role for cell-surface CSF-1 in osteoblast-mediated osteoclastogenesis. Calcif. Tissue Int. 2002;70:339–346. [PubMed]
44. Vaudry D, Stork PJ, Lazarovici P, Eiden LE. Signaling pathways for PC12 cell differentiation: making the right connections. Science. 2002;296:1648–1649. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation